NO20101069L - Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva - Google Patents

Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva

Info

Publication number
NO20101069L
NO20101069L NO20101069A NO20101069A NO20101069L NO 20101069 L NO20101069 L NO 20101069L NO 20101069 A NO20101069 A NO 20101069A NO 20101069 A NO20101069 A NO 20101069A NO 20101069 L NO20101069 L NO 20101069L
Authority
NO
Norway
Prior art keywords
antidepressants
hydrogen
affinity antagonists
certain nmda
fluorophenyl
Prior art date
Application number
NO20101069A
Other languages
English (en)
Inventor
Dennis Mccarthy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20101069L publication Critical patent/NO20101069L/no
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Anvendelse av visse lavaffinitet-NMDA-antagonister som antidepressive midler. Foretrukne forbindelser inkluderer forbindelser av formel (I) R2 | R5 R1 ? CH2 ??? N | R4 R3 (I) Hvor R1 er pyridyl, fenyl eller 4-fluorfenyl; R2 er fenyl eller 4-fluorfenyl; R3 er hydrogen, C1-6 alkyl eller metoksykarbonyl; R4 er hydrogen eller metyl; og R5 er hydrogen eller COCH2NH2, og farmasøytisk akseptable salter derav.
NO20101069A 1999-03-23 2010-07-27 Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva NO20101069L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901077A SE9901077D0 (sv) 1999-03-23 1999-03-23 Novel use
PCT/SE2000/000540 WO2000056324A1 (en) 1999-03-23 2000-03-21 The use of certain affinity nmda antagonists as antidepressants

Publications (1)

Publication Number Publication Date
NO20101069L true NO20101069L (no) 2001-09-06

Family

ID=20414989

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014345A NO330550B1 (no) 1999-03-23 2001-09-06 Anvendelse av NMDA-affinitetsantagonist som antidepressiva
NO20101069A NO20101069L (no) 1999-03-23 2010-07-27 Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20014345A NO330550B1 (no) 1999-03-23 2001-09-06 Anvendelse av NMDA-affinitetsantagonist som antidepressiva

Country Status (17)

Country Link
US (1) US6479553B1 (no)
EP (1) EP1162967A1 (no)
JP (1) JP4705717B2 (no)
KR (1) KR20010108368A (no)
CN (1) CN1160065C (no)
AR (1) AR029343A1 (no)
AU (1) AU774117B2 (no)
BR (1) BR0009225A (no)
CA (1) CA2359568A1 (no)
IL (1) IL145334A0 (no)
MX (1) MXPA01009448A (no)
MY (1) MY135916A (no)
NO (2) NO330550B1 (no)
NZ (1) NZ513148A (no)
SE (1) SE9901077D0 (no)
WO (1) WO2000056324A1 (no)
ZA (1) ZA200106859B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005116657A2 (en) * 2004-05-24 2005-12-08 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja) 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
EP1898890A1 (en) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
PE20120249A1 (es) 2008-12-24 2012-04-19 Astrazeneca Ab Compuestos etanaminicos
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
EP2791352A1 (en) * 2011-12-14 2014-10-22 Astrazeneca AB Gabr-a2 diagnostic
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
DE69317411T2 (de) * 1992-04-03 1998-07-30 Ab Astra, Soedertaelje Enantiomere 1-phenyl-2-(2-pyridinyl)ethylamin für die behandlung neurodegenerativer störungen
DE69809827D1 (de) * 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
SE9901077D0 (sv) 1999-03-23
NZ513148A (en) 2003-10-31
EP1162967A1 (en) 2001-12-19
IL145334A0 (en) 2002-06-30
NO20014345D0 (no) 2001-09-06
ZA200106859B (en) 2002-11-20
JP2002539256A (ja) 2002-11-19
BR0009225A (pt) 2001-12-26
AU774117B2 (en) 2004-06-17
AR029343A1 (es) 2003-06-25
MY135916A (en) 2008-07-31
CN1344157A (zh) 2002-04-10
CN1160065C (zh) 2004-08-04
JP4705717B2 (ja) 2011-06-22
US6479553B1 (en) 2002-11-12
NO330550B1 (no) 2011-05-16
AU4156100A (en) 2000-10-09
MXPA01009448A (es) 2002-08-06
WO2000056324A1 (en) 2000-09-28
NO20014345L (no) 2001-09-06
KR20010108368A (ko) 2001-12-07
CA2359568A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
TW330202B (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
MXPA04006322A (es) Derivados de 6-fluorobiciclo[3.1.0]hexano.
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
FR2805810B1 (fr) Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
YU17092A (sh) Derivati 2,4-diaminohinazolina
HUP9802304A2 (hu) Piridazin-3-on-származékok, intermedierjeik, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó herbicid készítmények
DK1539734T3 (da) Quinolylpropylpiperidinderivater og deres anvendelse som antimikrobielle midler
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
NO20015172L (no) 1-metyl-erytromycin-derivater
MY116280A (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
SE9703376D0 (sv) A new combination
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
SE0201658D0 (sv) Immediate release pharmaceutical formulation
CO5540322A2 (es) Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos
NO20012965L (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
EP1130015A4 (en) Pyridazinone derivatives
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists